Vaccinia

Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference

Retrieved on: 
Monday, February 12, 2024
Oncology, Health, Stem Cells, General Health, Pharmaceutical, Biotechnology, Immune system, Vaccinia, Neoplasm, Dove Medical Press, Cell, Conference, Supernova, Tumor microenvironment, Patient, Survival, Cancer, Vaccine

Calidi's systemic enveloped virotherapy program, ImmunoNova, leverages extensive experience in utilizing cells to protect, potentiate and deliver virotherapies.

Key Points: 
  • Calidi's systemic enveloped virotherapy program, ImmunoNova, leverages extensive experience in utilizing cells to protect, potentiate and deliver virotherapies.
  • Utilizing an engineered and enveloped vaccinia virus, ImmunoNova shows promising potential in targeting advanced metastatic disease across the body, while maintaining survival in the bloodstream.
  • Preclinical models have demonstrated ImmunoNova's efficacy in transforming tumor immune microenvironments and eradicating distant and diverse tumors.
  • “Calidi's groundbreaking systemic enveloped virotherapy holds immense promise in revolutionizing the treatment landscape for cancer patients with advanced solid tumors.

United States INVELTYS (Loteprednol Etabonate/KPI-121) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023
Health, Pharmaceutical, Eye, AOP, Research, Conjunctiva, Clinical trial, SWOT, Vaccinia, Pain, Chickenpox, Inflammation, Dietary supplement, Pharmaceutical industry, Telescopic sight

This report provides comprehensive insights about INVELTYS for acute ocular pain (AOP) in the United States.

Key Points: 
  • This report provides comprehensive insights about INVELTYS for acute ocular pain (AOP) in the United States.
  • A detailed picture of the INVELTYS for acute ocular pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the INVELTYS for acute ocular pain.
  • Further, it also consists of future market assessments inclusive of the INVELTYS market forecast analysis for acute ocular pain in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute ocular pain.
  • This report provides a detailed market assessment of INVELTYS for acute ocular pain in the United States.

United States INVELTYS (Loteprednol Etabonate/KPI-121) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 14, 2023
Health, Pharmaceutical, Eye, Research, Viral, Pain, Conjunctiva, Collagen, SWOT, Edema, Vaccinia, Glucocorticoid, Chickenpox, Inflammation, Poultry farming, Dietary supplement, Pharmaceutical industry

The "United States INVELTYS Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States INVELTYS Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about INVELTYS for acute pain in the United States.
  • A detailed picture of the INVELTYS for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the INVELTYS for acute pain.
  • This report provides a detailed market assessment of INVELTYS for acute pain in the United States.

Meridian Medical Technologies, LLC, and the European Commission’s DG HERA Sign Agreement for 13 Countries From the EEA to Purchase Tecovirimat SIGA

Retrieved on: 
Monday, October 23, 2023
Other Defense, Infectious Diseases, Contracts, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Defense, European Economic Area, Vaccinia, Medication, SIGA Technologies, Cowpox, Health Emergency Preparedness and Response Authority, Mpox, Meridian Medical Technologies, European Medicines Agency, JPA, MHRA, European, HERA, Smallpox, Tecovirimat, EMA, Joint, Gross metropolitan product, Medicines and Healthcare products Regulatory Agency, Health technology, Patient, Vaccine, Nursing, Meridian, EEA, EU

Meridian Medical Technologies, LLC (Meridian), a global health security leader in providing medical countermeasures, today announced a framework contract under the Joint Procurement Agreement (JPA) was signed between Meridian and the European Commission’s Directorates-General (DG) HERA (Health Emergency Preparedness and Response Authority).

Key Points: 
  • Meridian Medical Technologies, LLC (Meridian), a global health security leader in providing medical countermeasures, today announced a framework contract under the Joint Procurement Agreement (JPA) was signed between Meridian and the European Commission’s Directorates-General (DG) HERA (Health Emergency Preparedness and Response Authority).
  • As part of a promotional licensing agreement, Meridian is a global commercialization partner for SIGA Technologies, Inc. (NASDAQ: SIGA), which is the marketing authorization holder and manufacturer of Tecovirimat SIGA.
  • Under the JPA, 13 participating countries from the European Economic Area (EEA) (Contracting Parties) can now efficiently purchase Tecovirimat SIGA, which has been approved by the European Medicines Agency (EMA) and Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications.
  • This agreement will result in country-level procurement of oral Tecovirimat SIGA and serve as a template for future procurement opportunities.

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting

Retrieved on: 
Wednesday, October 4, 2023
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Contact, Ernest, Cerebral edema, Palace, Employment, Pain, Telecanthus, Incidence, Hilton New Orleans Riverside, Steroid, Viral, Macular edema, Herpes simplex, NYSE, Chickenpox, Magazine Street, Canal Street, Conjunctiva, EYE, Tchoupitoulas Street, Risk, Pigment, Intraocular pressure, SM, Optic nerve, FDA, INA War Museum, Iris, Andhra Pradesh Decentralisation and Inclusive Development of All Regions Act, 2020, Fungal infection, Poydras Street, Sclera, Eye, Bausch, History, Slit lamp, Glaucoma, Ocular hypertension, DED, Cornea, IOP, Contact lens, Infection, American Academy, Inflammation, Johnson & Johnson Vision, Vaccinia, Bausch & Lomb, Lens (vertebrate anatomy), Visual acuity, Pharmaceutical industry, Medical device, Hospital, Telescopic sight, Hotel, Gasoline, Nursing, Dietary supplement, Vaccine, Blinking, O.D, Patient

Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.

Key Points: 
  • Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.
  • Another educational event will highlight practical patient cases using products from across the company’s consumer, vision care and pharmaceutical portfolios.
  • The Bausch + Lomb schedule at AAOpt:
    “Clinical Dry Eye Findings in Patients Using a Novel Lipid-Containing Eye Drop.” Joshi et al.
  • “Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, Reduces Corneal Staining Across All Regions of the Cornea.” Fahmy et al.

Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation

Retrieved on: 
Wednesday, September 20, 2023
GMP, LSE, Official List, Poxviridae, Oxford, QC, European Union (Withdrawal) Act 2018, London Stock Exchange, AGM, Equity, Immunotherapy, OXB, Lentivirus, CDMO, EBITDA, Acquisition, VWAP, Financial Conduct Authority, Vivisection, Potyvirus, ABL, Depreciation, Growth, Virus, Companies Act 2006, Completion, MVA, Vaccine, Fine chemical, Retail, Bookkeeping, Oxford Biomedica, EU, Vaccinia, European, Adenoviridae

596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).

Key Points: 
  • 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).
  • This Proposed Transaction would form part of Oxford Biomedica’s transformation to be a world-leading quality focused and innovation-led CDMO in the cell and gene therapy field.
  • As at 31 December 2022, ABL Europe had earnings before interest tax and depreciation (EBITDA) of c.€(1.7)m and gross assets of c.€23.6m.
  • Currently, the Proposed Transaction would constitute a Class 2 transaction for the purposes of the UK Financial Conduct Authority’s Listing Rules.

Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform

Retrieved on: 
Wednesday, June 28, 2023
Vaccine, S&P, Antigen, Human, Norovirus, Rotavirus, Vaccination, Biotechnology, Smallpox, Mpox, Capsid, Bluewater, Infection, Antibody, CDC, Monkeypox virus, Discovery, Animal, Patient, Risk, Blood, Korea Disease Control and Prevention Agency, VLP, Cincinnati Children's Hospital Medical Center, Mouse, FDA, Family, World Health Organization, Vaccinia

CINCINNATI, Ohio, June 28, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company spanning multiple sectors, today announced preliminary preclinical data supporting the use of its norovirus shell and protrusion (“S&P”) virus-like particle (“VLP”) platform to develop a novel monkeypox vaccine candidate.

Key Points: 
  • CINCINNATI, Ohio, June 28, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company spanning multiple sectors, today announced preliminary preclinical data supporting the use of its norovirus shell and protrusion (“S&P”) virus-like particle (“VLP”) platform to develop a novel monkeypox vaccine candidate.
  • In August 2022, Blue Water announced plans to explore the development of its novel monkeypox vaccine candidate by presenting monkeypox antigens within the S&P platform.
  • Following successful integration of selected antigens into the platform, mice were immunized with the vaccine candidate and analyzed for antibody levels in the blood.
  • “We are thrilled to announce this exciting initial step in development of our monkeypox vaccine candidate,” said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water.

Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, April 26, 2023
Surgery, Medical Devices, Health, Pharmaceutical, Optical, Tradition, Intraocular lens, Aperture, ASCRS, Astigmatism, Pain, Employment, Telecanthus, Incidence, Patient, Outcome, Viral, Steroid, Herpes simplex, NYSE, Chickenpox, Very-small-aperture terminal, Conjunctiva, Cornea, Comparative Effectiveness Research Translation Network, SM, Optic nerve, Cataract, FDA, Emerging technologies, Fungal infection, Refractive surgery, Use, Sclera, Eye, Bausch, History, Thought, American Society of Cataract and Refractive Surgery, Slit lamp, ARMOR, Glaucoma, DED, IOP, Contact lens, Infection, OVD, Inflammation, Vaccinia, Bausch & Lomb, Range, Convention (norm), Visual acuity, Society, Pharmaceutical industry, Telescopic sight, Telescope, Wood drying, Dentistry, Hospital, Retail, Veterinary medicine, Fused quartz, Vaccine, Dietary supplement, Emmetropia, Refraction, IOL

The posters and presentations include two studies assessing the new StableVisc™ cohesive ophthalmic viscosurgical device, which Bausch + Lomb commercially launched this month.

Key Points: 
  • The posters and presentations include two studies assessing the new StableVisc™ cohesive ophthalmic viscosurgical device, which Bausch + Lomb commercially launched this month.
  • Others include a retrospective chart review on the use of LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% in refractive surgery and numerous presentations focused on Bausch + Lomb surgical IOL pipeline programs.
  • New data from the Bausch + Lomb Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study will also be presented.
  • “Clinical Evaluation of the Outcomes of Two Preloaded Monofocal IOLs Implanted Bilaterally in Cataract Patients.” Shultz et al.

Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting

Retrieved on: 
Thursday, April 20, 2023
Science, Biotechnology, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Hypersensitivity, Meibomian gland, Fetus, Safety, Cataract, Fungus, Dose, Development, Floater, Data analysis, Photophobia, Patient, Risk, Macular edema, Association for Research in Vision and Ophthalmology, Virus, NYSE, Chickenpox, Canker, ARVO, Pregnancy, Conjunctiva, Photopsia, Viral, HPA, Chemosis, Intraocular pressure, Administration, Uveitis, Bacteria, Chalazion, Hypothalamic–pituitary hormone, FDA, Lomb, Hyperglycemia, Perception, Efficacy, Eye, History, Sanfilippo, ARMOR, Triamcinolone, Cover My Eyes (Pain and Heaven), Intraocular lens, Glaucoma, Cornea, Research and development, Nursing, Telecanthus, Vaccinia, Asbell, Bausch & Lomb, Meibomian gland dysfunction, Visual acuity, Pharmaceutical industry, Wood drying, Vaccine, Telescopic sight, Dietary supplement, Ophthalmology, Kalahari Desert

“Comparative Evaluation of the Attributes of a New Cohesive Ophthalmic Viscosurgical Device.” Hosten et al.

Key Points: 
  • “Comparative Evaluation of the Attributes of a New Cohesive Ophthalmic Viscosurgical Device.” Hosten et al.
  • “Early Adoption of Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A Physician Survey.” Chang et al.
  • “Longitudinal Analysis of In Vitro Antibiotic Resistance Among Ocular Staphylococci Collected in the ARMOR study.” Asbell et al.
  • To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch .

Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses

Retrieved on: 
Tuesday, April 11, 2023
Microtubule, Infection, University of Rochester Medical Center, Human, Partnership, University, EEV, Marketing, Public, Mpox, COVID-19, African, Animal efficacy rule, CFR, Smallpox, Research, Cmax, Cavg, Associate, Development, Patient, Multiple organ dysfunction syndrome, Dentistry, Immunology, Viral, FDA, Death, BARDA, Virus, Pneumonia, Vaccine, Microbiology, Vaccinia

MIAMI, FL, April 11, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced results from a preclinical in vitro study evaluating the effects of sabizabulin against prototypical poxvirus, vaccinia virus, which demonstrated that sabizabulin prevented both the release of poxvirus from infected cells and the spread of poxvirus to healthy cells. These preclinical study results support the expansion of sabizabulin’s program into additional indications to potentially treat the lethal smallpox virus infection or other related infections if a worldwide emergency outbreak occurs.

Key Points: 
  • These preclinical study results support the expansion of sabizabulin’s program into additional indications to potentially treat the lethal smallpox virus infection or other related infections if a worldwide emergency outbreak occurs.
  • The purpose of the study was to evaluate the mechanism of antiviral efficacy of sabizabulin, a novel microtubule disruptor, against the prototypical poxvirus vaccinia in cell culture.
  • To assess the ability of sabizabulin to slow or stop vaccinia virus cell-to-cell spread, BSC40 cells were treated with different concentrations of sabizabulin before inoculation with vaccinia virus at a low multiplicity of infection.
  • In this study, sabizabulin, by disrupting microtubules, was able to prevent the export and release of infectious vaccinia virus.